Use of nicotinic acetylcholine receptor alpha 7 activators
AssigneeNovartis AG
InventorsThérèse Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
Life of this patent
Estimating the term…
Abstract
The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
Claims5
A method for the treatment or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, comprising:
- administering to said subject a therapeutically effective amount of (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane
- in free base form or in acid addition salt form.
A method for the treatment or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, comprising administering to said subject:
- a therapeutically effective amount of (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in free base form or in acid addition salt form;
- and
- levodopa, wherein the levodopa is administered in an amount that is reduced by at least 10% relative to a daily dosage of 250-1500 mg/day that would be effective for treating a patient not being administered the therapeutically effective amount of (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane.
Dependencies are inferred from the claim text.